Form 8-K - Current report:
SEC Accession No. 0001213900-24-031860
Filing Date
2024-04-10
Accepted
2024-04-10 15:46:00
Documents
14
Period of Report
2024-04-04
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0203653-8k_actavia.htm   iXBRL 8-K 38954
2 LETTER FROM MAZARS USA LLP DATED APRIL 4, 2024 ea020365301ex16-1_actavia.htm EX-16.1 4177
  Complete submission text file 0001213900-24-031860.txt   214312

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rasp-20240404.xsd EX-101.SCH 3006
4 XBRL LABEL FILE rasp-20240404_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE rasp-20240404_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0203653-8k_actavia_htm.xml XML 3403
Mailing Address 5 PENN PLAZA, 19TH FLOOR, #1954 NEW YORK NY 10001
Business Address 5 PENN PLAZA, 19TH FLOOR, #1954 NEW YORK NY 10001 646-396-4087
ACTAVIA LIFE SCIENCES, INC. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 333-191083 | Film No.: 24835644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)